Metex Pen

Methotrexate, the active ingredient in Metex Pen, is an antimetabolite (folate antagonist) presented as a subcutaneous injection pen for subcutaneous use. It is employed to treat inflammatory arthritis, certain autoimmune disorders and selected cancers in adult and pediatric patients. GNH USA supplies Metex Pen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methotrexate is a folate antagonist used across several inflammatory and malignant disease pathways. - Rheumatoid arthritis: reduces joint inflammation and slows structural damage. - Psoriatic arthritis: alleviates skin and joint symptoms while limiting disease progression. - Juvenile idiopathic arthritis: controls systemic inflammation and improves functional outcomes. - Crohn's disease: induces remission of intestinal inflammation. - Certain cancers (e.g., leukemia, lymphoma): interferes with rapid cell proliferation as part of chemotherapy protocols.

Methotrexate can cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea or vomiting: gastrointestinal upset that may improve with food. - Fatigue: persistent tiredness often reported during treatment. - Oral mucositis: soreness or ulceration of the mouth lining. - Elevated liver enzymes: mild, transient changes in hepatic function tests. - Cytopenias: mild reductions in white blood cells or platelets.

Serious or Rare Side Effects: - Severe liver toxicity: potential for fibrosis or cirrhosis with prolonged use. - Pulmonary fibrosis: interstitial lung disease presenting with cough and dyspnea. - Bone marrow suppression: profound pancytopenia increasing infection risk. - Renal impairment: acute kidney injury from precipitation of drug crystals. - Life‑threatening infections: opportunistic infections due to immunosuppression.

Methotrexate requires careful monitoring and specific safety measures before and during therapy. - Pregnancy: contraindicated (Category X); teratogenic risk mandates effective contraception. - Renal function: assess baseline creatinine and adjust dose in impairment. - Hepatic function: monitor liver enzymes regularly; avoid in pre‑existing severe liver disease. - Hematologic status: perform complete blood counts to detect cytopenias early. - Infection risk: defer treatment in active infections and avoid live vaccines. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate interacts with several medicines that can alter its efficacy or toxicity.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate toxicity. - Trimethoprim‑sulfamethoxazole: heightens risk of myelosuppression. - Live vaccines: may cause severe infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Azathioprine: additive bone‑marrow suppression requiring blood‑count surveillance. - Proton pump inhibitors: may affect methotrexate absorption and clearance. - Alcohol: potentiates hepatic toxicity; limit consumption.